Valneva and Pfizer announced positive immunogenicity and safety data from their Phase 2 study of a second booster dose for their Lyme disease vaccine candidate, VLA15. The data shows a robust immune response and a favorable safety profile, with the second booster providing similar benefits to the first. The companies are currently conducting two Phase 3 trials with the goal of submitting marketing applications to the FDA and EMA in 2026.